Prevention of diabetic complications by activation of Nrf2: Diabetic cardiomyopathy and nephropathy

Experimental Diabetes Research

Volumn 2012, Issue , 2012, Pages

  Li, Bing ^a,b,c   Liu, Shujun ^b   Miao, Lining ^a   Cai, Lu ^c  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^b Jilin Province People's Hospital   (China)

^c University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CINNAMALDEHYDE; GLUTATHIONE REDUCTASE; INSULIN; KI 67 ANTIGEN; MAGNESIUM LITHOSPERMATE; OLTIPRAZ; PENTAERYTHRITYL TETRANITRATE; REACTIVE OXYGEN METABOLITE; RESVERATROL; SULFORAPHANE; TELMISARTAN; TERT BUTYLHYDROQUINONE; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA1; TRANSKETOLASE; ANTIOXIDANT; NFE2L2 PROTEIN, HUMAN;

DETOXIFICATION; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE COURSE; FATALITY; HEART FUNCTION; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; KIDNEY FUNCTION; LIPID DIET; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVIEW; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; GENE EXPRESSION REGULATION; INFLAMMATION; METABOLISM; MOUSE;

ANIMALS; ANTIOXIDANTS; DIABETES COMPLICATIONS; DIABETIC CARDIOMYOPATHIES; DIABETIC NEPHROPATHIES; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MICE; MODELS, BIOLOGICAL; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84862282913     PISSN: 16875214     EISSN: 16875303     Source Type: Journal    
DOI: 10.1155/2012/216512     Document Type: Review

References (46)

1. Orasanu G., Plutzky J., The pathologic continuum of diabetic vascular disease Journal of the American College of Cardiology 2009 53 5, supplement S35 S42
2. Mann J. F., Schmieder R. E., McQueen M., Dyal L., Schumacher H., Pogue J., Wang X., Maggioni A., Budaj A., Chaithiraphan S., Dickstein K., Keltai M., Metsrinne K., Oto A., Parkhomenko A., Piegas L. S., Svendsen T. L., Teo K. K., Yusuf S., Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial The Lancet 2008 372 9638 547 553
3. Cai L., Kang Y. J., Oxidative stress and diabetic cardiomyopathy: a brief review Cardiovascular Toxicology 2001 1 3 181 193 (Pubitemid 37013746)
4. Inoguchi T., Li P., Umeda F., Yu H. Y., Kakimoto M., Imamura M., Aoki T., Etoh T., Hashimoto T., Naruse M., Sano H., Utsumi H., Nawata H., High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells Diabetes 2000 49 11 1939 1945
5. Nishikawa T., Edelstein D., Du X. L., Yamagishi S. I., Matsumura T., Kaneda Y., Yorek M. A., Beebe D., Oates P. J., Hammes H. P., Glardino I., Brownlee M., Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage Nature 2000 404 6779 787 790 (Pubitemid 30212409)
6. Rask-Madsen C., King G. L., Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes Nature Clinical Practice Endocrinology Metabolism 2007 3 1 46 56 (Pubitemid 46006612)
7. Jung K. A., Kwak M. K., The Nrf2 system as a potential target for the development of indirect antioxidants Molecules 2010 15 10 7266 7291
8. Luo Z. F., Qi W., Feng B., Mu J., Zeng W., Guo Y. H., Pang Q., Ye Z. L., Liu L., Yuan F. H., Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome Life Sciences 2011 88 11-12 512 520
9. Kobayashi M., Yamamoto M., Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species Advances in Enzyme Regulation 2006 46 1 113 140 (Pubitemid 44301353)
10. Sykiotis G. P., Bohmann D., Stress-activated cap'n'collar transcription factors in aging and human disease Science Signaling 2010 3 112, article re3
11. McMahon M., Itoh K., Yamamoto M., Hayes J. D., Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression The Journal of Biological Chemistry 2003 278 24 21592 21600 (Pubitemid 36792558)
12. de Haan J. B., Nrf2 activators as attractive therapeutics for diabetic nephropathy Diabetes 2011 60 11 2683 2684
13. Xue M., Qian Q., Adaikalakoteswari A., Rabbani N., Babaei-Jadidi R., Thornalley P. J., Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease Diabetes 2008 57 10 2809 2817
14. Negi G., Kumar A., Joshi R. P., Sharma S. S., Oxidative stress and Nrf2 in the pathophysiology of diabetic neuropathy: old perspective with a new angle Biochemical and Biophysical Research Communications 2011 408 1 1 5
15. Pi J., Zhang Q., Fu J., Woods C. G., Hou Y., Corkey B. E., Collins S., Andersen M. E., ROS signaling, oxidative stress and Nrf2 in pancreatic beta-cell function Toxicology and Applied Pharmacology 2010 244 1 77 83
16. He X., Kan H., Cai L., Ma Q., Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes Journal of Molecular and Cellular Cardiology 2009 46 1 47 58
17. Jiang T., Huang Z., Lin Y., Zhang Z., Fang D., Zhang D. D., The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy Diabetes 2010 59 4 850 860
18. Ungvari Z., Bailey-Downs L., Gautam T., Jimenez R., Losonczy G., Zhang C., Ballabh P., Recchia F. A., Wilkerson D. C., Sonntag W. E., Pearson K., de Cabo R., Csiszar A., Adaptive induction of NF-E2-related factor-2-driven antioxidant genes in endothelial cells in response to hyperglycemia American Journal of Physiology 2011 300 4 H1133 H1140
19. Hur K. Y., Kim S. H., Choi M. A., Williams D. R., Lee Y. H., Kang S. W., Yadav U. C., Srivastava S. K., Jung M., Cho J. W., Kim S. G., Kang E. S., Lee E. J., Lee H. C., Protective effects of magnesium lithospermate B against diabetic atherosclerosis via Nrf2-ARE-NQO1 transcriptional pathway Atherosclerosis 2010 211 1 69 76
20. Tan Y., Ichikawa T., Li J., Si Q., Yang H., Chen X., Goldblatt C. S., Meyer C. J., Li X., Cai L., Cui T., Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo Diabetes 2011 60 2 625 633
21. Yoh K., Hirayama A., Ishizaki K., Yamada A., Takeuchi M., Yamagishi S. I., Morito N., Nakano T., Ojima M., Shimohata H., Itoh K., Takahashi S., Yamamoto M., Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice Genes to Cells 2008 13 11 1159 1170
22. Zheng H., Whitman S. A., Wu W., Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy Diabetes 2011 60 11 3055 3066
23. Okouchi M., Okayama N., Alexander J. S., Aw T. Y., NRF2-dependent glutamate-L-cysteine ligase catalytic subunit expression mediates insulin protection against hyperglycemia-induced brain endothelial cell apoptosis Current Neurovascular Research 2006 3 4 249 261 (Pubitemid 44706249)
24. Song M. Y., Kim E. K., Moon W. S., Park J. W., Kim H. J., So H. S., Park R., Kwon K. B., Park B. H., Sulforaphane protects against cytokine- and streptozotocin-induced -cell damage by suppressing the NF- B pathway Toxicology and Applied Pharmacology 2009 235 1 57 67
25. Negi G., Kumar A., Sharma S. S., Nrf2 and NF- B modulation by sulforaphane counteracts multiple manifestations of diabetic neuropathy in rats and high glucose-induced changes Current Neurovascular Research 2011 8 4 294 304
26. Aleksunes L. M., Reisman S. A., Yeager R. L., Goedken M. J., Klaassen C. D., Nuclear factor erythroid 2-related factor 2 deletion impairs glucose tolerance and exacerbates hyperglycemia in type 1 diabetic mice Journal of Pharmacology and Experimental Therapeutics 2010 333 1 140 151
27. Yu Z., Shao W., Chiang Y., Foltz W., Zhang Z., Ling W., Fantus I. G., Jin T., Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 (NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice Diabetologia 2011 54 4 922 934
28. Li H., Zhang L., Wang F., Shi Y., Ren Y., Liu Q., Cao Y., Duan H., Attenuation of glomerular injury in diabetic mice with tert-butylhydroquinone through nuclear factor erythroid 2-related factor 2-dependent antioxidant gene activation American Journal of Nephrology 2011 33 4 289 297
29. Schuhmacher S., Oelze M., Bollmann F., Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy Diabetes 2011 60 10 2608 2616
30. He M., Siow R. C., Sugden D., Gao L., Cheng X., Mann G. E., Induction of HO-1 and redox signaling in endothelial cells by advanced glycation end products: a role for Nrf2 in vascular protection in diabetes Nutrition, Metabolism and Cardiovascular Diseases 2011 21 4 277 285
31. Palsamy P., Subramanian S., Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling Biochimica et Biophysica Acta 2011 1812 7 719 731
32. Fujita H., Fujishima H., Morii T., Modulation of renal superoxide dismutase by telmisartan therapy in C57BL/6- Ins2 (Akita) diabetic mice Hypertension Research 2012 35 2 213 220
33. Aggarwal B. B., Bhardwaj A., Aggarwal R. S., Seeram N. P., Shishodia S., Takada Y., Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies Anticancer Research 2004 24 5 2783 2840 (Pubitemid 39409568)
34. Palsamy P., Subramanian S., Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats Biomedicine Pharmacotherapy 2008 62 9 598 605
35. Liby K., Hock T., Yore M. M., Suh N., Place A. E., Risingsong R., Williams C. R., Royce D. B., Honda T., Honda Y., Gribble G. W., Hill-Kapturczak N., Agarwal A., Sporn M. B., The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling Cancer Research 2005 65 11 4789 4798 (Pubitemid 40740817)
36. Shin S., Wakabayashi J., Yates M. S., Wakabayashi N., Dolan P. M., Aja S., Liby K. T., Sporn M. B., Yamamoto M., Kensler T. W., Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-Imidazolide European Journal of Pharmacology 2009 620 13 138 144
37. Sussan T. E., Rangasamy T., Blake D. J., Malhotra D., El-Haddad H., Bedja D., Yates M. S., Kombairaju P., Yamamoto M., Liby K. T., Sporn M. B., Gabrielson K. L., Champion H. C., Tuder R. M., Kensler T. W., Biswal S., Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice Proceedings of the National Academy of Sciences of the United States of America 2009 106 1 250 255
38. Thimmulappa R. K., Fuchs R. J., Malhotra D., Scollick C., Traore K., Bream J. H., Trush M. A., Liby K. T., Sporn M. B., Kensler T. W., Biswal S., Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils Antioxidants Redox Signaling 2007 9 11 1963 1970 (Pubitemid 47622348)
39. Ichikawa T., Li J., Meyer C. J., Janicki J. S., Hannink M., Cui T., Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes PloS One 2009 4 12
40. McMahon G. M., Forman J. P., Bardoxolone methyl, chronic kidney disease, and type 2 diabetes The New England Journal of Medicine 2011 365 18 1746 1747
41. Pergola P. E., Krauth M., Huff J. W., Ferguson D. A., Ruiz S., Meyer C. J., Warnock D. G., Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD American Journal of Nephrology 2011 33 5 469 476
42. Pergola P. E., Raskin P., Toto R. D., Meyer C. J., Huff J. W., Grossman E. B., Krauth M., Ruiz S., Audhya P., Christ-Schmidt H., Wittes J., Warnock D. G., Bardoxolone methyl and kidney function in CKD with type 2 diabetes The New England Journal of Medicine 2011 365 4 327 336
43. Rogacev K. S., Bittenbring J. T., Fliser D., Bardoxolone methyl, chronic kidney disease, and type 2 diabetes The New England Journal of Medicine 2011 365 18 1745 1747
44. Upadhyay A., Sarnak M. J., Levey A. S., Bardoxolone methyl, chronic kidney disease, and type 2 diabetes The New England Journal of Medicine 2011 365 18 1746 1747
45. van Laecke S., Vanholder R., Bardoxolone methyl, chronic kidney disease, and type 2 diabetes The New England Journal of Medicine 2011 365 18 1745 1747
46. Ramprasath T., Murugan P. S., Kalaiarasan E., Gomathi P., Rathinavel A., Selvam G. S., Genetic association of Glutathione peroxidase-1 (GPx-1) and NAD(P)H:quinone oxidoreductase 1(NQO1) variants and their association of CAD in patients with type-2 diabetes Molecular and Cellular Biochemistry 2011 361 1-2 143 150